EMA Fast-Tracks Review of Experimental Pancreatic Cancer Drug
The European Medicines Agency (EMA) is fast-tracking the review of an experimental drug for metastatic pancreatic cancer, a disease associated with a six-month life expectancy. This initiative aims to address a high unmet medical need.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.